Bioverativ, A Sanofi Company

This study tested an experimental drug called BIVV020 in 12 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal was to see if the drug could safely raise and maintain platelet counts without needing r…

This early-stage study tested a single injection of an experimental drug called BIVV001 in 6 adults with type 2N or type 3 von Willebrand disease, a rare bleeding disorder. The main goals were to see how the drug behaves in the body and whether it is safe. The study did not aim t…

This study tested a new medicine called SAR445088 in 98 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that causes weakness and numbness in the arms and legs. The goal was to see if the drug can help control symptoms and reduce disability. Parti…

This study tested a new medicine called BIVV001 in 74 children under 12 with severe hemophilia A, a condition where blood does not clot properly. The goal was to see if the drug is safe and can prevent bleeding episodes when given regularly. The drug is a lab-made clotting factor…

This study tested a new medicine called BIVV001 in 159 people aged 12 and older with severe hemophilia A. The goal was to see if regular injections could prevent bleeding episodes and improve joint health and quality of life. Results showed the treatment helped control bleeding, …

This early-stage study tested a single dose of an experimental drug called BIVV020 in 12 adults with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. The main goal was to check safety and how well the drug is tolerated. Researchers also l…